Governance

INSTITUTIONAL BIOSAFETY COMMITTEE CHARGE

The Institutional Biosafety Committee is responsible for enforcing policies and guidelines related to the use of all potentially hazardous biological agents including but not limited to infectious agents, human and non human primate materials (including established cell lines), known regulated carcinogens, select agents, recombinant DNA and studies involving human gene transfer. The Committee is responsible for ensuring that research involving these agents is conducted in a manner that does not endanger the researcher, laboratory worker, human research subjects, the public or the environment.

The Institutional Biosafety Committee is responsible for:

  • Formulating and implementing policies related to the safe use of biological materials and known chemical carcinogens;
  • Reviewing all research protocols involving biological materials and known chemical carcinogens;
  • Approving or disapproving such projects based on their potential hazard and proposed containment procedures;
  • Establishing, approving and monitoring proper laboratory conditions and procedures required for such projects;
  • Reviewing the qualifications and training of investigators and laboratory personnel engaged in such research to ensure appropriate laboratory safety techniques are used;
  • Ensuring adoption of proper disposal and decontamination procedures;
  • Adopting emergency plans covering accidental spills and personnel contamination resulting from research;
  • Ensuring the investigation and reporting of any significant problems with or violations of the NIH and/or CDC Guidelines, as specified in the NIH Guidelines for Research Involving Recombinant DNA Molecules and the "Biosafety in Microbiological and Biomedical Laboratories" respectively.

    The Committee follows the NIH Guidelines for Research Involving Recombinant DNA Molecules on the use of recombinant DNA and human gene transfer and the CDC/NIH guidelines, "Biosafety in Microbiological and Biomedical Laboratories," in addition to implementing more restrictive guidelines, as needed.

    The Institutional Biosafety Committee meets at least once per month. Fifty one percent of the voting membership is necessary to establish a quorum for conducting business. Committee members are selected from a pool of faculty with expertise in the properties and safe use of human and non-human primate materials, infectious agents, carcinogens, select agents, recombinant DNA and human gene transfer trials. The pool of faculty selected to serve on the committee shall meet the requirements specified in the NIH Guidelines for Research Involving Recombinant DNA Molecules. Members must attend three-fourths of the meetings or they will be removed from the committee the following year.

    The Institutional Biosafety Committee shall consist of at least 12 voting members appointed by the President or his designee. Membership includes, at minimum:

  • six faculty members who are either physicians or particularly knowledgeable in the fields listed above;
  • the Director of Animal Resources;
  • a member representing the Laboratory Technical Staff;
  • two outside community members; and
  • two ex officio members–the Associate Senior Vice President for Career and Protective Services, and a Biological Safety Officer.

    Ad hoc Committee members will be used for various situations as they arise.

    The Committee reports administratively to the President through the Senior Vice President for Administration and works closely with the Associate Senior Vice President for Career and Protective Services, whose office provides the staff support for the Committee.

    July 2011